ClinicalTrials.gg
Active, not recruitingNCT06817577SPROUTUpdated Sep 25, 2026

NG004 in Spinal Cord Injury Patients

A Phase 1 interventional study of NG004 in Acute Spinal Cord Injury (SCI), Spinal Cord Diseases and Central Nervous System Diseases, sponsored by NovaGo Therapeutics AG. Active, not recruiting at 6 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Primary conditionSpinal Cord InjuriesRegistry: Spinal Cord DiseasesReclassifiedWhy we changed it
Registry
Spinal Cord Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Spinal Cord Injuries
Why
  1. The study's listed conditions name Spinal Cord Injuries, a narrower term within Spinal Cord Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by NovaGo Therapeutics AG · Phase 1, Interventional, and Treatment

How we know

Updated Sep 25, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Spinal Cord Injuries with a site in Germany — 3 open to participants now, 6 under way, none of them phase 3. Spinal Cord Injuries · Germany.

Planned enrollment
10th of 14
20 · median 38
Started
2024
the only one that year
Phase 1
4 of 22
1 open now
Registered
19th of 22
by date
Lead sponsor
2 of 22
NovaGo Therapeutics AG

Among the 22 studies in Spinal Cord Injuries with a site in Germany, this one is the 10th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2024, is one of 4 in phase 1, and was the 19th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

3 of the 22 studies in Spinal Cord Injuries with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Spinal Cord Injuries with a site in Germany, or all of them as a file.
02

Study summary

This is the FIH, multicenter, open-label, sequential, multiple ascending dose trial of NG004 in patients with acute incomplete cervical SCI. The trial will evaluate the safety, tolerability, and PK of 4 dose regimens of NG004, and will evaluate the maximum tolerated dose of NG004. The trial consists of Part A (the dose escalation) and Part B (the PK-confirmation at 2 dose levels from Part A).

03

Conditions studied

  • Acute Spinal Cord Injury (SCI)
  • Spinal Cord Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Trauma, Nervous System
  • Spinal Cord Injuries (SCI)
  • Wounds and Injuries

Keywords

  • Acute spinal cord injury
  • Nogo-A
  • SPROUT
  • Regeneration
04

In context

Spinal Cord Injuries Reclassified

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

This study's planned enrollment of 20 is below the median of 24 across 1,639 interventional studies indexed under Spinal Cord Injuries.

Browse Spinal Cord Injuries studies →

Lead sponsor

NovaGo Therapeutics AG is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Compared within Spinal Cord Injuries, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Spinal Cord Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute incomplete cervical SCI (Neurological level of injury C1 ≤ lesion ≤ C8) with confirmed classification of American Spinal Injury Association (ASIA) impairment scale (AIS) C-D at Screening
  • 4-28 days post-injury
  • No required mechanical ventilation or patients that not completely depend on mechanical ventilation
  • Hemodynamically and clinical stable patient according to the acute SCI condition at baseline

Exclusion criteria

Exclusion Criteria:

  • Trauma caused by ballistic or other injury that directly penetrates the spinal cord including gunshot and knife wounds
  • Multiple levels of spinal cord lesions
  • Major brachial or lumbar plexus damage/trauma
  • Significant head trauma or other injury that was, in the opinion of the investigator, sufficient to interfere with the assessment of the spinal cord function
  • Other significant pre-existing or current severe systemic disease such as lung, liver (exception: history of uncomplicated Hepatitis A), gastrointestinal, cardiac, immunodeficiency (including anamnestic known ) or kidney disease; or active
  • History of or an acute episode of Multiple Sclerosis or Guillain-Barre syndrome History of recent (6 months) meningitis or meningoencephalitis
  • History of epilepsy
  • History of or current disease
  • Patients with uncontrolled bleeding diathesis and/or who require concomitant therapeutic anticoagulation and not related to SCI
  • Presence of any unstable medical or psychiatric condition
  • Drug dependence any time during the 6 month's preceding trial entry
  • Pregnant or nursing women
  • History of a life-threatening allergic or immune mediated reaction
  • Patients with the presence of infection around the location where the spinal needle insertions are planned for applying the intrathecal injections
  • Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations
  • Patients who are unconscious
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    NG004

    Drug: NG004

Interventions

  • DrugNG004

    repeated intrathecal injections of NG004

07

What researchers measure

Primary outcomes

  1. Type, frequency, severity, and causal relationship of adverse events (AEs), serious AEs, and adverse drug reactions

    Time frame: From treatment start up to 6 months

Secondary outcomes

  1. Maximum Plasma Concentration [Cmax] in serum

    Time frame: After first and last intrathecal injection, measured at pre-dose and 1, 3, 6, 24, 48 hours post-dose.

  2. Half-life in serum [T1/2]

    Time frame: After last intrathecal injection up to 6 months

Other outcomes

  1. Effect on motor function as Change from Baseline in ISNCSCI upper extremities motor score (UEMS), according to the International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol

    The ISNCSCI bilateral Upper Extremity Motor Score (UEMS) is determined by examining the muscle function within each of the 5 myotomes encompassing arm and hand function on each side of the body. A score ranging from 0 to 5 can be given to each myotome tested resulting in a maximum score of 50. Higher values indicate better recovery.

    Time frame: Baseline up to 6 months

  2. Effect on daily life functioning according to change in Version III of the Spinal Cord Independence Measure (SCIM-III)

    The SCIM III questionnaire self-care score assesses activities of daily living including feeding, bathing, dressing, and grooming. The self-care score ranges 0-20. The higher scores correspond to better ability to carry out the self-care activities.

    Time frame: Baseline to 6 months

08

Study locations

6 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Mar 2027, 27 months after the start.

Of 51 phase 1 interventional studies under Spinal Cord Injuries, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Feb 10, 2025
StartActual
Dec 18, 2024
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Recruiting→Active, not recruiting
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06817577
Lead sponsor
NovaGo Therapeutics AG
Responsible party
Sponsor
First posted
Feb 10, 2025
Start date
Dec 18, 2024
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Director of Clinical Research
study director · NovaGo Therapeutics AG

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion